Uses
JUVMO is indicated for the treatment of Parkinson’s disease (PD) in adults. JUVMO is a non-ergot dopamine agonist indicated for the treatment of Parkinson’s disease in adults.
Source: US FDA prescribing information
Molecule
Tavapadon
Available on request
- Presentations
- 5
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Tavapadon is a prescription medicine indicated for the treatment of Parkinson’s disease (PD) in adults. It is available as tablets and kits for oral use. MedsAcross supplies Tavapadon for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- US FDA first approval
- 25 September 2026
- EU status
- Not recorded
- Orphan designation
- Not recorded
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Oral
- Dosage forms
- Tablet, Kit
- Identifiers
- UNII PT4P8MJP8LCAS 1643489-24-0DrugBank DB14899Q108670876
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
Tavapadon is a selective partial agonist at the dopamine D1 and D5 receptor subtypes (D 1 /D 5 ).
Source: US FDA prescribing information
Dosing overview
JUVMO is taken orally once daily, with or without food. See Table 1 for the recommended titration schedule. Recommended maintenance dosage is 5 mg orally once daily. The dosage may be increased to a maximum of 15 mg once daily based on tolerability and clinical response.
Source: US FDA prescribing information
Contraindications
None. None.
Source: US FDA prescribing information
Warnings and precautions
May cause hypotension/orthostatic hypotension. May cause problems with impulse control or compulsive behaviors. Consider dose reductions or stopping JUVMO. May cause hallucinations and psychotic-like behavior. The risk of hallucinations may be increased when co-administered with strong CYP3A inhibitors during the maintenance phase. May cause dyskinesia or exacerbate pre-existing dyskinesia.
Source: US FDA prescribing information
Side effects
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Hypotension/Orthostatic Hypotension Impulse Control/Compulsive Behaviors Hallucinations and Psychotic-like Behavior Dyskinesia Most common adverse reactions (≥ 5%) for JUVMO without concomitant levodopa were nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth, and anxiety. Most common adverse reactions (≥ 5%) for JUVMO with concomitant levodopa were nausea, dyskinesia, dizziness, headache, hallucinations, and orthostatic hypotension.
Source: US FDA prescribing information
Interactions
7 D RUG INTERACTIONS Avoid concomitant use of strong or moderate CYP3A inhibitors during titration and strong CYP3A inducers during titration and maintenance of JUVMO. Recommended JUVMO dosage modifications during maintenance dosing: Strong and moderate CYP3A inhibitors: Decrease dosing frequency. Strong CYP3A inducers: Concomitant use is not recommended. Moderate CYP3A inducers (long-term): Increase dosing frequency. CYP3A substrates: If JUVMO is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, consider a dosage modification of such substrates when initiating or discontinuing JUVMO.
Source: US FDA prescribing information
Storage
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
5 presentations of Tavapadon, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Juvmo kit | AbbVie | US FDA | Available on request |
| Juvmo 10 mg tabletOral | AbbVie | US FDA | Available on request |
| Juvmo 15 mg tabletOral | AbbVie | US FDA | Available on request |
| Juvmo 5 mg tabletOral | AbbVie | US FDA | Available on request |
| Juvmo 0.25 mg tabletOral | AbbVie | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 25 September 2026 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Questions and answers
Is Tavapadon available for export from India?
Yes, on request. MedsAcross lists 5 presentations of Tavapadon and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Tavapadon have?
The catalogue lists 1 brand names for Tavapadon, including Juvmo.
Is Tavapadon approved by the US FDA?
Yes. The US FDA first approved Tavapadon on 25 September 2026, according to Drugs@FDA.
Does Tavapadon need cold chain shipping?
No listed presentation of Tavapadon is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
References
- JUVMO prescribing information (AbbVie). U.S. National Library of Medicine, DailyMed. Retrieved 8 October 2026
Request Tavapadon for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.